Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 133

1.

Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors.

Hymel D, Grant RA, Tsuji K, Yaffe MB, Burke TR Jr.

Bioorg Med Chem Lett. 2018 Aug 19. pii: S0960-894X(18)30692-9. doi: 10.1016/j.bmcl.2018.08.018. [Epub ahead of print]

PMID:
30174151
2.

HIV-1 Integrase-Targeted Short Peptides Derived from a Viral Protein R Sequence.

Zhao XZ, Métifiot M, Kiselev E, Kessl JJ, Maddali K, Marchand C, Kvaratskhelia M, Pommier Y, Burke TR Jr.

Molecules. 2018 Jul 26;23(8). pii: E1858. doi: 10.3390/molecules23081858.

3.

HIV-1 Integrase Inhibitors That Are Broadly Effective against Drug-Resistant Mutants.

Smith SJ, Zhao XZ, Burke TR Jr, Hughes SH.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01035-18. doi: 10.1128/AAC.01035-18. Print 2018 Sep.

PMID:
29987149
4.

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.

Smith SJ, Zhao XZ, Burke TR Jr, Hughes SH.

Retrovirology. 2018 May 16;15(1):37. doi: 10.1186/s12977-018-0420-7.

5.

Developing and Evaluating Inhibitors against the RNase H Active Site of HIV-1 Reverse Transcriptase.

Boyer PL, Smith SJ, Zhao XZ, Das K, Gruber K, Arnold E, Burke TR Jr, Hughes SH.

J Virol. 2018 Jun 13;92(13). pii: e02203-17. doi: 10.1128/JVI.02203-17. Print 2018 Jul 1.

PMID:
29643235
6.

Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates.

Nanna AR, Li X, Walseng E, Pedzisa L, Goydel RS, Hymel D, Burke TR Jr, Roush WR, Rader C.

Nat Commun. 2017 Oct 24;8(1):1112. doi: 10.1038/s41467-017-01257-1.

7.

Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors.

Zhao XZ, Smith SJ, Maskell DP, Métifiot M, Pye VE, Fesen K, Marchand C, Pommier Y, Cherepanov P, Hughes SH, Burke TR Jr.

J Med Chem. 2017 Sep 14;60(17):7315-7332. doi: 10.1021/acs.jmedchem.7b00596. Epub 2017 Aug 10.

8.

Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents.

Park JE, Hymel D, Burke TR Jr, Lee KS.

F1000Res. 2017 Jun 29;6:1024. doi: 10.12688/f1000research.11398.1. eCollection 2017. Review.

9.

Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets.

Lu X, Nowicka U, Sridharan V, Liu F, Randles L, Hymel D, Dyba M, Tarasov SG, Tarasova NI, Zhao XZ, Hamazaki J, Murata S, Burke TR Jr, Walters KJ.

Nat Commun. 2017 Jun 9;8:15540. doi: 10.1038/ncomms15540.

10.

Stable and Potent Selenomab-Drug Conjugates.

Li X, Nelson CG, Nair RR, Hazlehurst L, Moroni T, Martinez-Acedo P, Nanna AR, Hymel D, Burke TR Jr, Rader C.

Cell Chem Biol. 2017 Apr 20;24(4):433-442.e6. doi: 10.1016/j.chembiol.2017.02.012. Epub 2017 Mar 16.

11.

Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.

Zhao XZ, Hymel D, Burke TR Jr.

Bioorg Med Chem. 2017 Oct 1;25(19):5041-5049. doi: 10.1016/j.bmc.2017.02.063. Epub 2017 Feb 28.

PMID:
28285924
12.

Corrigendum: Phosphatase-Stable Phosphoamino Acid Mimetics That Enhance Binding Affinities with the Polo-Box Domain of Polo-like Kinase 1.

Hymel D, Burke TR Jr.

ChemMedChem. 2017 Feb 3;12(3):278. doi: 10.1002/cmdc.201700019. Epub 2017 Jan 23. No abstract available.

PMID:
28185436
13.

Phosphatase-Stable Phosphoamino Acid Mimetics That Enhance Binding Affinities with the Polo-Box Domain of Polo-like Kinase 1.

Hymel D, Burke TR Jr.

ChemMedChem. 2017 Feb 3;12(3):202-206. doi: 10.1002/cmdc.201600574. Epub 2017 Jan 9. Erratum in: ChemMedChem. 2017 Feb 3;12 (3):278.

14.

Application of oxime-diversification to optimize ligand interactions within a cryptic pocket of the polo-like kinase 1 polo-box domain.

Zhao XZ, Hymel D, Burke TR Jr.

Bioorg Med Chem Lett. 2016 Oct 15;26(20):5009-5012. doi: 10.1016/j.bmcl.2016.08.098. Epub 2016 Sep 2.

15.

Chemically Programmed Bispecific Antibodies in Diabody Format.

Walseng E, Nelson CG, Qi J, Nanna AR, Roush WR, Goswami RK, Sinha SC, Burke TR Jr, Rader C.

J Biol Chem. 2016 Sep 9;291(37):19661-73. doi: 10.1074/jbc.M116.745588. Epub 2016 Jul 21.

16.

Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.

Métifiot M, Johnson BC, Kiselev E, Marler L, Zhao XZ, Burke TR Jr, Marchand C, Hughes SH, Pommier Y.

Nucleic Acids Res. 2016 Aug 19;44(14):6896-906. doi: 10.1093/nar/gkw592. Epub 2016 Jul 1.

17.

HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases.

Zhao XZ, Smith SJ, Maskell DP, Metifiot M, Pye VE, Fesen K, Marchand C, Pommier Y, Cherepanov P, Hughes SH, Burke TR Jr.

ACS Chem Biol. 2016 Apr 15;11(4):1074-81. doi: 10.1021/acschembio.5b00948. Epub 2016 Feb 5.

18.

Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.

Lee KS, Burke TR Jr, Park JE, Bang JK, Lee E.

Trends Pharmacol Sci. 2015 Dec;36(12):858-877. doi: 10.1016/j.tips.2015.08.013. Epub 2015 Oct 17. Review.

19.

6,7-Dihydroxyisoindolin-1-one and 7,8-Dihydroxy-3,4-Dihydroisoquinolin- 1(2H)-one Based HIV-1 Integrase Inhibitors.

Zhao XZ, Metifiot M, Smith SJ, Maddali K, Marchand C, Hughes SH, Pommier Y, Burke TR Jr.

Curr Top Med Chem. 2016;16(4):435-40. Review.

PMID:
26268341
20.

Neighbor-directed histidine N (τ)-alkylation: A route to imidazolium-containing phosphopeptide macrocycles.

Qian WJ, Park JE, Grant R, Lai CC, Kelley JA, Yaffe MB, Lee KS, Burke TR Jr.

Biopolymers. 2015 Nov;104(6):663-73. doi: 10.1002/bip.22698.

Supplemental Content

Loading ...
Support Center